I'm curious if the Phase 2 OC trial will be done at DF/BI, like the Phase 1 was. Sure would be a vote of confidence by the DF investigators, showing that they deeply want to continue to be a part of Kevetrin's development. (Presenting at oncology seminars is good, but that's kind of obligatory as well as in their self-interest.
Market Data 
Markets 
AI
